MG
PDLI

Michael Gelband’s PDL BioPharma, Inc. PDLI Stock Holding History

Michael Gelband’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,158
Closed -$126K – 2588
2020
Q3 		$126K Buy
40,158
+27,724
+223% +$88.6K ﹤0.01% 1562
2020
Q2 		$36K Buy
+12,434
New +$39.3K ﹤0.01% 1694
2019
Q4 		– Sell
-103,011
Closed -$223K – 2070
2019
Q3 		$223K Buy
+103,011
New +$275K 0.01% 1066

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Michael Gelband's PDLI Position: Q4 2020 in Review

Michael Gelband sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 40,158 shares — an estimated $126K sold.

Michael Gelband first reported a position in PDLI in Q3 2019 and held it in 3 quarters. The position peaked at $223K in Q3 2019. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Michael Gelband reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Michael Gelband sold 40,158 PDL BioPharma, Inc. shares in Q4 2020, an estimated $126K.
  • Michael Gelband first reported a position in PDL BioPharma, Inc. in Q3 2019 and held it in 3 quarters.
  • Michael Gelband's PDL BioPharma, Inc. position peaked at $223K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on ExodusPoint Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.